AGN · ASX

Argenica Therapeutics Ltd (ASX:AGN)

AU$0.8

 0.02 (2.564%)
ASX:Live
19/02/2025 03:56:41 PM
Hammer Bullish HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

AGN Overview

AGN Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About AGN

Website

N/A

Telephone

Address

Description

Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.

AGN Price Chart

Key Stats

Market Cap

AU$99.91M

PE

13.90

EV/EBITDA

0.0

Dividends Overview

DIV Yield

1.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.54 - 0.99

Trade Value (12mth)

AU$32,039.00

1 week

-4.29%

1 month

18.18%

YTD

22.83%

1 year

39.29%

All time high

1.02

Key Fundamentals

EPS 3 yr Growth

274.50%

EBITDA Margin

N/A

Operating Cashflow

-$5m

Free Cash Flow Return

-46.80%

ROIC

-50.70%

Interest Coverage

N/A

Quick Ratio

6.70

Other Data

Shares on Issue (Fully Dilluted)

128m

HALO Sector

Next Company Report Date

20-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

AGN Announcements

Latest Announcements

Date Announcements

11 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

04 February 25

ARG-007 Shows Significant Neuroprotection in Main TBI Study

×

ARG-007 Shows Significant Neuroprotection in Main TBI Study

04 February 25

Updated - Main TBI Injury Study Annoucement

×

Updated - Main TBI Injury Study Annoucement

30 January 25

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

×

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

30 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

10 December 24

Phase 2 Stroke Clinical Trial Update

×

Phase 2 Stroke Clinical Trial Update

02 December 24

Non-Executive Director Appointment

×

Non-Executive Director Appointment

02 December 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

21 November 24

$2.76m R&D Tax Incentive Cash Rebate Received for FY24

×

$2.76m R&D Tax Incentive Cash Rebate Received for FY24

13 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

13 November 24

AGM Chair's Address & MD Presentation

×

AGM Chair's Address & MD Presentation

13 November 24

Final Director's Interest Notice

×

Final Director's Interest Notice

01 November 24

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

×

Positive DSMB Safety Outcome & Phase 2 Trial Progress Update

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report - updated

×

Quarterly Activities/Appendix 4C Cash Flow Report - updated

30 October 24

FDA Grants ODD & RPDD for Second Drug in Treatment of HIE

×

FDA Grants ODD & RPDD for Second Drug in Treatment of HIE

29 October 24

Investor Presentation

×

Investor Presentation

24 October 24

Non-Executive Director Retirement

×

Non-Executive Director Retirement

11 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

07 October 24

Argenica Appoints VP of Product Development

×

Argenica Appoints VP of Product Development

25 September 24

Positive Results in Key IND Enabling Studies

×

Positive Results in Key IND Enabling Studies

24 September 24

Application for quotation of securities - AGN

×

Application for quotation of securities - AGN

17 September 24

Date of AGM & Closing Date For Director Nominations

×

Date of AGM & Closing Date For Director Nominations

17 September 24

New Appointments to the Board of Directors

×

New Appointments to the Board of Directors

17 September 24

Initial Director's Interest Notice x2

×

Initial Director's Interest Notice x2

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

1.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

AGN Shortsell

Frequently Asked Questions

The current share price of Argenica Therapeutics Ltd (AGN:ASX) is AU$0.8.
The 52-week high share price for Argenica Therapeutics Ltd (AGN:ASX) is AU$0.99.
The 52-week low share price for Argenica Therapeutics Ltd (AGN:ASX)? is AU$0.54.
The current TTM dividend payout for Argenica Therapeutics Ltd (AGN:ASX) is 1.00.
Argenica Therapeutics Ltd (AGN:ASX) does not pay a dividend.
Argenica Therapeutics Ltd (AGN:ASX) has a franking level of 0.0%.
Argenica Therapeutics Ltd (AGN:ASX) is classified in the Healthcare.
The current P/E ratio for Argenica Therapeutics Ltd (AGN:ASX) is 13.90.